FDA still probing Friday's J&J recall Friday's recall of more than 40 widely used nonprescription products for children and infants such as Tylenol, Motrin, Zyrtec and Benadryl affects at least 1,500 product lots, Diamond tools FDA spokeswoman Elaine Bobo also told Reuters,Diamond Saw Blade adding it is unclear how many actual bottles are affected.

She said it is too early to tell if the agency will take further action against Johnson & Johnson and the FDA is still gathering information in the Tylenol case.

The FDA asked Johnson & Johnson to recall products on Friday following a routine inspection of its Fort Washington, Pennsylvania, facility April 19-30, Bobo said. The drugmaker issued the recall late Friday night.

"Our thought was because these over-the-counter products are so widely used and because it hit such vulnerable populations with infants and children, that we really needed to get the word out there to at least give consumers a heads' up before we had all the specifics," Bobo said.

The FDA said on Friday the company was implementing Diamond tools the voluntary recall due to manufacturing deficiencies that might affect quality, purity or potency.

Despite the recall, Johnson & Johnson shares closed up 1.6 percent,Diamond Saw Blade or $1.03, to $65.33 on Monday, roughly in line with the market overall.

Sanford Bernstein analyst Derrick Sung said that, while the recall was "yet another hit" to the reputation of Johnson & Johnson's consumer business, "the impact of that alone on the overall company is still relatively minor." Johnson & Johnson, with $61.9 billion in sales last year, sells a wide array of prescription drugs, medical devices and consumer products.

While investors appeared to shrug off the recall on Monday, "if they don't handle it well, I think it's a bigger concern later on," said Noble Financial Group analyst Jan Wald.

Diamond Saw Blade If it "looks like it's hiding something or Diamond tools isn't fully disclosing ... I think that's where it can get hurt," Wald said.